In this report, our understanding of how natural products can simultaneously modulate the GLP-1 and TXNIP–thioredoxin axes to achieve a synergistic therapeutic effect in MetS is therefore being advanced from a phenomenological listing of bioactivities to a more accurate and mechanistic understanding. This evidence concerns the gene TXNIP and metabolic syndrome.